Understanding the in vivo transport of nanoparticles provides guidelines for designing
nanomedicines with higher efficacy and fewer side effects. Among many factors, the size of …

This review aims to provide a systemic analysis of the in vivo, as well as subcellular, fate of
polymeric micelles (PMs), starting from the entry of PMs into the body. Few PMs are able to …

The use of small interfering RNAs (siRNAs) has been under investigation for the treatment of
several unmet medical needs, including acute lung injury/acute respiratory distress …

The pulmonary route has long been used for drug administration for both local and systemic
treatment. It possesses several advantages, which can be categorized into physiological, ie …

Pulmonary fibrosis results from dysregulated lung repair and involves multiple cell types.
The role of endothelial cells (EC) in lung fibrosis is poorly understood. Using single cell RNA …

Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation
and destruction of the lung air–blood barrier, leading to irreversible and substantial …

The lack of effective treatments for pulmonary diseases presents a significant global health
burden, primarily due to the challenges posed by the pulmonary barrier that hinders drug …

The recent emergence of nanomedicine has revolutionized the therapeutic landscape and
necessitated the creation of more sophisticated drug delivery systems. Polymeric …

Since the inception of the concept of “magic bullet”, nanoparticles have evolved to be one of
the most effective carriers in drug delivery. Nanoparticles improve the therapeutic efficacy of …

Pulmonary drug delivery is a highly attractive topic for the treatment of infectious lung
diseases. Drug delivery via the pulmonary route offers unique advantages of no first-pass …